Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies

NCT00820508 is registered in ClinicalTrials.gov with Chroma Therapeutics as lead sponsor.

NCT NCT00820508
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00820508 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies
Lead sponsor
Chroma Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2008
Completion date
July 31, 2011
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hematological disease, lymphoid malignancies